Sudden cardiac death in nonischemic cardiomyopathy

Kadakia, Rikin; Link, Mark S.; Dominic, Paari; Morin, Daniel P.

doi:10.1016/j.pcad.2019.05.002

Cited by 18 publications

(8 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three studies found increased arrhythmias during the long (3-day) versus 2-day interval between hemodialysis sessions, suggesting the magnitude of volume retention (or accumulation of uremic toxins) may play a role [33, 36, 37]. In the general population, the treatment of nonatherosclerotic SCD similarly remains unclear [35], although genetic testing is suggested in patients with a family history of an early cardiac event. Based on the current study, we cannot recommend such an approach in patients with ESKD.…”

Section: Discussion/conclusionmentioning

confidence: 99%

The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis

et al. 2021

View full text Add to dashboard Cite

Introduction: Patients with chronic kidney disease experience high rates of cardiovascular mortality and morbidity. When kidney disease progresses to the need for dialysis, sudden cardiac death (SCD) accounts for 25–35% of all cardiovascular deaths. The objective was to determine if rare genetic variants known to be associated with cardiovascular death in the general population are associated with SCD in patients undergoing hemodialysis. Methods: We performed a case-control study comparing 126 (37 African American [AfAn] and 89 European ancestry [EA]) SCD subjects and 107 controls (34 AfAn and 73 EA), matched for age, sex, self-reported race, dialysis duration (<2, 2–5 and >5 years), and the presence or absence of diabetes mellitus. To target the coding regions of genes previously reported to be associated with 15 inherited cardiac conditions (ICCs), we used the TruSight Cardio Kit (Illumina, San Diego, CA, USA) to capture the genetic regions of interest. In all, the kit targets 572-kb regions that include the protein-coding regions and 40-bp 5′ and 3′ end-flanking regions of 174 genes associated with the 15 ICCs. Using the sequence data, burden tests were conducted to identify genes with an increased number of variants among SCD cases compared to matched controls. Results: Eleven genes were associated with SCD, but after correction for multiple testing, none of the 174 genes were identified as having more variants in the SCD cases than the matched controls, including previously identified genes. Secondary burden tests grouping variants based on diseases and gene function did not produce statistically significant associations. Discussion/Conclusions: We found no associations between genes known to be associated with ICCs and SCD in our sample of patients undergoing hemodialysis. This suggests that genetic causes are unlikely to be a major pathogenic factor in SCD in hemodialysis patients, although our sample size limits definitive conclusions.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Sensitivity analysis was performed by excluding patients with a history of cardiomyopathy or valvular heart disease, as cardiomyopathies are a common cause of SCD (32,33); a systematic review identi ed cardiomyopathies as one of the top causes of SCD in Chinese patients (34). Similarly, studies have found associations of aortic valve disease and mitral valve prolapse with VA/SCD (35)(36)(37)(38).…”

Section: Implications Of Subgroup and Sensitivity Analysesmentioning

confidence: 99%

Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared to metformin: a population-based cohort study

Tse

Lee

Hui

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Commonly prescribed diabetic medications such as metformin and sulfonylurea may be associated with different arrhythmogenic risks. This study compared the risk of ventricular arrhythmia or sudden cardiac death (VA/SCD) between metformin and sulfonylurea in patients with type 2 diabetes. Methods: Patients aged 40 years or older who were diagnosed with type-2 diabetes mellitus or prescribed anti-diabetic agents in Hong Kong between 1st January 2009 and 31st December 2009 were included and followed up till 31st December 2019. Patients prescribed with both metformin and sulfonylurea or had prior myocardial infarction were excluded. The study outcome was a composite of VA/SCD. Metformin users and sulfonylurea users were matched at a 1:1 ratio by propensity score matching. Results: The study cohort consisted of 5756 metformin users (48.00% male, age 68±11 years, mean follow-up 5.04±2.57 years) and 5756 sulfonylurea users (50.30% male, age 69±11 years, mean follow-up 5.04±2.54 years). Sulfonylurea was associated with higher risk of VA/SCD than metformin (hazard ratio 1.84 [1.56 - 2.16], p<0.001). Such difference was consistently observed in subgroup analyses stratifying for insulin usage or known coronary heart disease. Conclusion: Sulfonylurea use is associated with higher risk of VA/SCD than metformin in patients with type 2 diabetes.

show abstract

“…При ангиографическом исследовании диагностируют систолическое сужение пораженной коронарной артерии, исчезающее во время диастолы. При пробе с нитроглицерином во внутримиокардиальном сегменте наблюдают еще большее сужение просвета за счет расширения неизмененных сосудов и феномена «обкрадывания» [37].…”

Section: Fibromuscular Dysplasia Of the Coronary Arteries фибромускулunclassified

Modern Concepts of Fibromuscular Dysplasia of the Coronary Arteries

Трисветова

2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Fibromuscular dysplasia of the coronary arteries is a rare non-atherosclerotic and non-inflammatory vascular lesion that is asymptomatic until serious complications develop: stenosis, dissection, rupture, sudden cardiac death. Since there are no long-term numerous clinical observations of patients with fibromuscular dysplasia of the coronary arteries, recommendations have not been developed for diagnosing and treating the disease, which often manifests with acute coronary syndrome. In 2014, the European Consensus was published, and in 2019, the first international consensus document on the diagnosis and treatment of fibromuscular dysplasia with lesions of vessels from different regions (renal, cerebrovascular, coronary, and others). The documents state that the development of fibromuscular dysplasia of the coronary arteries considers the participation of the PHACTR1 gene mutation and the transcriptional activity of the EDN1 gene, smoking, prolonged exertion of the vascular wall, and possibly female sex hormones. In the case of acute coronary syndrome, the most informative diagnostic method is computed tomography with angiography, which reveals a smooth narrowing of the lumen in the middle or distal section in the epicardial artery, often due to intramural hematoma, and also finds dissection, spasm, and tortuous vessel. Additional diagnostic methods ‒ intravascular ultrasound and optical coherence tomography allow differentiation of fibromuscular dysplasia with atherosclerosis of the coronary artery, vasculitis, and other diseases. The choice of treatment tactics for fibromuscular dysplasia of the coronary arteries depends on the severity of the clinical manifestations ‒ conservative medical treatment and interventional methods are used.

show abstract

Sudden cardiac death in nonischemic cardiomyopathy

Cited by 18 publications

References 76 publications

The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis

The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis

Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared to metformin: a population-based cohort study

Modern Concepts of Fibromuscular Dysplasia of the Coronary Arteries

Contact Info

Product

Resources

About